Proud to be part of the team that is redefining the standard of care for rheumatic diseases through transformational science with Daniel Cua, Ph.D.,
#mycompany #immunology
Many people living with psoriatic arthritis (PsA) are struggling to find the right treatment and experience less daily pain.
At the American College of Rheumatology’s Annual Meeting, we’re presenting data from 39 abstracts sharing disease insights and the impact of our rheumatology portfolio, including data showin our therapy provided substantial and durable radiographic and joint efficacy, skin clearance, pain relief and a consistent safety profile through two years for people living with psoriatic arthritis.
Janssen Immunology is redefining the standard of care for rheumatic diseases through transformational science and a deeper understanding of the impact of these conditions on patients. Learn more: https://bit.ly/3bOHTZn
#Immunology #rheumatology #PsoriaticArthritis #ACR2021 #ACR21
To view or add a comment, sign in
To view or add a comment, sign in
Our team has pioneered critical research in the interleukin (IL)-23 pathway and helped to transform the lives of patients with immune-mediated diseases. However, millions are still in need of treatments that adequately meet their goals. #MyCompany remains committed to this vital pathway research to apply insights across diseases with similar pathologies and advance much-needed therapies for patients.
At Janssen, we're pioneering research to reveal connections between immune pathways and disease pathologies that can lead to scientific breakthroughs for patients with immunological disorders. A recent supplement in Rheumatology features insights into pathway discovery research from Daniel Cua, Ph.D., IL-23 Pathway Leader, and Jonathan Sherlock, M.D., Director, Translational Sciences. Learn more: https://bit.ly/3BnlPiS
To view or add a comment, sign in
To view or add a comment, sign in
Very excited to share this latest perspective on the importance of the IL-23 pathway in immunology with Daniel Cua, Ph.D., and Jonathan Sherlock
I'm pleased to share this latest perspective on the importance of the IL-23 pathway in immune research and the many patients it can help. This research has already yielded significant insights for those working against immune-mediated diseases, and has the potential to generate many more.
![The Importance of Interleukin-23 in Immune-Mediated Diseases]()
Daniel Cua, Ph.D., on LinkedIn
To view or add a comment, sign in
To view or add a comment, sign in
I’m excited to share this latest publication in the British Journal of Dermatology. Congratulations, team! #MyCompany
Newly published results in the British Journal of Dermatology show the majority of adult patients with moderate to severe #PsO who continued treatment with our medication through five years maintained both skin clearance and improvement in patient-reported outcomes in health-related quality of life. Our team is committed to advancing novel solutions that can help the 125 million people worldwide living with PsO, an inflammatory skin disease with no known cure.
To view or add a comment, sign in
To view or add a comment, sign in
Very proud to share our new data in The Lancet Rheumatology! Congratulations to the entire team. #MyCompany Philip Mease Chetan Karyekar, MD, PhD Soumya Chakravarty, MD, PhD, FACP, FACR Alexa Kollmeier, MD Elizabeth Hsia MD MSCE Bei Zhou Xenofon Baraliakos Denis Poddubnyy
Psoriatic arthritis (PsA) can cause a variety of symptoms, and sacroiliac joint involvement is one of its earliest manifestations. Physicians and their patients should be informed about all possible manifestations during treatment discussions, and our team is dedicated to researching our medicines across the multi-faceted symptoms of PsA, including sacroiliitis.
In a recent study, our medicine was found to provide durable improvements in axial symptoms in PsA patients with imaging-confirmed sacroiliitis.
#PsoriaticArthritis
To view or add a comment, sign in
To view or add a comment, sign in
I’m excited to share this video of enthesitis expert Dennis McGonagle highlighting the results of our recent publication in Rheumatology. We continually strive to meet psoriatic arthritis patients’ needs through research into its multifaceted symptoms. #MyCompany
One-year results showing the effect of our medicine on enthesitis in adults with active psoriatic arthritis were recently published in Rheumatology. Watch study author Professor Dennis McGonagle explain the importance of addressing enthesitis in the treatment of PsA.
To view or add a comment, sign in
To view or add a comment, sign in
I’m proud to share our latest publication of #MyCompany’s safety data as part of our continued efforts to support #PsoriaticArthritis patients with vital research and insights.
At Janssen, we are dedicated to providing safe, effective treatment options for #PsoriaticArthritis (PsA). Pooled safety data recently published in The Journal of Rheumatology showed our medicine was well tolerated through one year in patients with PsA.
Watch as Global Medical Affairs Leader May Shawi explains the importance of these comprehensive safety data in PsA.
To view or add a comment, sign in
To view or add a comment, sign in
I’m excited to share that #MyCompany is presenting 34 abstracts at #EULAR2021, which includes data from our novel therapy to treat the challenging condition of psoriatic arthritis.
Psoriatic Arthritis (PsA) is a chronic and painful disease of the joints, skin and soft tissues with no known cure. Our team is committed to developing novel therapies to address patients’ unmet needs and create a brighter future for all those impacted by PsA. We’re proud to be among the leaders presenting the latest rheumatology science at #EULAR2021. Learn more here: https://bit.ly/3ceW4HD
#PsoriaticArthritis #rheumatology
To view or add a comment, sign in
To view or add a comment, sign in
Very excited to share this article about our publication on IL-23 Targeting for Enthesis in Psoriatic Arthritis. Thanks @ Daniel Cua, Ph.D., for your work on IL-23!
#mycompany
https://lnkd.in/gS-gjcM
To view or add a comment, sign in
To view or add a comment, sign in
